Establishment Labs (ESTA) Set to Announce Quarterly Earnings on Thursday

Establishment Labs (NASDAQ:ESTA) is scheduled to release its earnings data after the market closes on Thursday, November 7th. Analysts expect Establishment Labs to post earnings of ($0.61) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Establishment Labs (NASDAQ:ESTA) last posted its earnings results on Tuesday, August 6th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). The business had revenue of $44.12 million for the quarter, compared to the consensus estimate of $43.10 million. Establishment Labs had a negative return on equity of 220.67% and a negative net margin of 54.97%. The business’s revenue was down 9.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.65) earnings per share. On average, analysts expect Establishment Labs to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Establishment Labs Stock Performance

ESTA stock opened at $47.90 on Wednesday. The business’s 50-day moving average price is $43.25 and its two-hundred day moving average price is $45.89. The company has a current ratio of 4.44, a quick ratio of 2.91 and a debt-to-equity ratio of 4.30. The firm has a market cap of $1.34 billion, a PE ratio of -15.40 and a beta of 1.20. Establishment Labs has a 1-year low of $16.96 and a 1-year high of $60.12.

Analysts Set New Price Targets

Several research firms have weighed in on ESTA. Stephens reiterated an “overweight” rating and set a $68.00 target price on shares of Establishment Labs in a report on Wednesday, August 7th. BTIG Research lifted their price target on Establishment Labs from $62.00 to $65.00 and gave the company a “buy” rating in a research note on Monday, October 14th. JPMorgan Chase & Co. dropped their price target on Establishment Labs from $61.00 to $50.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 7th. Finally, Citigroup lifted their price target on Establishment Labs from $45.00 to $50.00 and gave the company a “neutral” rating in a research note on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Establishment Labs has a consensus rating of “Moderate Buy” and an average price target of $58.83.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.